Man­u­fac­tur­ing roundup: Cel­l­Vax part­ners up with Ther­a­gent for PhII tri­al; Ox­ford Bio­med­ica sells fa­cil­i­ty for $70M+

The cell ther­a­py CD­MO Ther­a­gent has roped in a man­u­fac­tur­ing con­tract for a Phase II tri­al.

The com­pa­ny is work­ing on Cel­l­Vax Ther­a­peu­tics’ im­munother­a­py can­di­date FK-PC101, a cell-based au­tol­o­gous can­cer vac­cine for prostate can­cer pa­tients who have a high rate of re­cur­rence af­ter prosta­te­c­to­my. The size of the deal was not dis­closed.

In an email to End­points News, Ther­a­gent COO Jeff Mas­ten said the CD­MO was se­lect­ed af­ter a con­sul­tant’s rec­om­men­da­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.